Internal Medicine/Hematology/Oncology


Haifaa Abdulhaq, MD

Assistant Clinical Professor, UCSF


  Medical School: Damascus University, Syria
  Residency: Damascus University Hospitals, Syria
Western Pennsylvania Hospital, Pittsburgh, PA
  Fellowship Rheumatology, Damascus University Hospitals, Syria
Hematology/Oncology, Western Pennsylvania Hospitals, Pittsburgh, PA
  Board Certified: Internal Medicine, Hematology, Oncology
  Awards and Recognition:
  1. National achievement award
  2. Ranked 2nd among  Syrian high school graduates (50,000 students)
  3. Al Basel Prize
  4. Ranked 1st among Damascus University School of medicine graduates (> 700 students)
  5. Best junior house staff award
  6. Best senior house staff award
  1. Abdulhaq H,  Rossetti JM, Shadduck RK,. The myelodysplastic syndromes. Oncology Special Edition. 2006; 9(6): 97-101

  2. Lister J, Abdulhaq H. The role of Proteasome Inhibition in Cancer Therapy. The American Journal of Oncology Review. 2006; 5 (6), supp (6): 15-16.

  3. Abdulhaq H,  Rossetti JM, Shadduck RK.   The myelodysplastic syndromes. Clinical Oncology News. 4/ 2006.

  4. Shadduck RK, Latsko JM,  Rossetti JM, Haq B, Abdulhaq H. Recent advances in myelodysplastic syndromes. Experimental Hematology. 2007; 35 (4): 137-143

  5. Abdulhaq H,  Rossetti, JM.  The role of azacitidine in treatment of myelodysplastic syndromes. Expert opinion on investigational drugs. 2007; 16 (12): 1967-1975

  6. Abdulhaq H,  Rossetti JM, Shadduck RK,. Myelodysplasia: Recent advances: Oncology Special Edition. 2007; 10: 145-152

  7. Talreja N, Abdulhaq H, Shadduck RK, et al. Erythroid variant of chronic myeloid leukemia, letter to the editor. Leukemia. 2008; 22 (4): 867-870

  8. Abdulhaq H,  C Geyer. Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer. Accepted for publication in the American Journal of Clinical Oncology.




    Abdulhaq H,
    Stefanovic A,  Sudan N,  Rossetti JM
      Response to therapy with azacitidine (AZA) in patients with myelodysplastic syndromes.   2002
    Kaplan R, Abduhaq H, Kennedy M   Phase I/II Study of the Use of Rituximab in Patients with Antiphospholipid Syndrome (APLS)   2005- present
    Haq B, Abdulhaq H,  Rossetti JM,  Lynch E,  Lister J   Ki 67 and Activated Caspase 3 as outcome predictors in patients with mantle cell lymphoma (MCL)   2007- present
    Abdulhaq H, Haq B,  Rossetti JM,  Shadduck RK,  Lister J, et al.   Response to azacitidine in myelomonocytic leukemia   2008